AU2002352391A1 - A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus - Google Patents
A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitusInfo
- Publication number
- AU2002352391A1 AU2002352391A1 AU2002352391A AU2002352391A AU2002352391A1 AU 2002352391 A1 AU2002352391 A1 AU 2002352391A1 AU 2002352391 A AU2002352391 A AU 2002352391A AU 2002352391 A AU2002352391 A AU 2002352391A AU 2002352391 A1 AU2002352391 A1 AU 2002352391A1
- Authority
- AU
- Australia
- Prior art keywords
- pyridil
- thiazolidine
- dione
- ethoxy
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0129877.7 | 2001-12-13 | ||
| GB0129850.4 | 2001-12-13 | ||
| GB0129849A GB0129849D0 (en) | 2001-12-13 | 2001-12-13 | Novel pharmaceutical |
| GB0129850A GB0129850D0 (en) | 2001-12-13 | 2001-12-13 | Novel pharmaceutical |
| GB0129877A GB0129877D0 (en) | 2001-12-13 | 2001-12-13 | Novel pharmaceutical |
| GB0129849.6 | 2001-12-13 | ||
| PCT/GB2002/005678 WO2003050116A1 (en) | 2001-12-13 | 2002-12-13 | A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002352391A1 true AU2002352391A1 (en) | 2003-06-23 |
Family
ID=27256353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002352391A Abandoned AU2002352391A1 (en) | 2001-12-13 | 2002-12-13 | A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002352391A1 (en) |
| WO (1) | WO2003050116A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR047541A1 (en) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | PHOSPHATE OF 5 - [[4- [2-METHYL-2-PYRIDINYL-AMINO-ETOXI] PHENYL] METHYL] -2,4 THYZOLIDINADION (ROSIGLITAZONE) AND ITS POLYMORPHIC FORMS |
| DE102005034406A1 (en) * | 2005-07-22 | 2007-02-01 | Ratiopharm Gmbh | New salts of rosiglitazone |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0306228B1 (en) * | 1987-09-04 | 1999-11-17 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| GB9726568D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| IL146110A0 (en) * | 1999-04-23 | 2002-07-25 | Smithkline Beecham Plc | Thiazolidinedione derivative and its use as antidiabetic |
-
2002
- 2002-12-13 WO PCT/GB2002/005678 patent/WO2003050116A1/en not_active Ceased
- 2002-12-13 AU AU2002352391A patent/AU2002352391A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003050116A1 (en) | 2003-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2001005I2 (en) | 5-A4-A2- (N-methyl-N- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2,4-dione, maleic acid salt | |
| IL146111A0 (en) | 5-[4-[2-(n-methyl-n-(2-pyridyl) amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt | |
| NO20003069D0 (en) | 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione-maleic acid salt hydrate as a pharmaceutical | |
| AP2000001830A0 (en) | Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt | |
| GC0000250A (en) | 5-Ä4-Ä2-(N-methyl-n-(2-pyridyl) amino) ethoxyÜ benzylÜthiazolidine-2,4-dione maleci acid salt | |
| AP9901696A0 (en) | Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl)amino) ehtoxy benzyl)thiazolidine-2,4-dione | |
| IL162853A0 (en) | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus | |
| AU2002352391A1 (en) | A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus | |
| SI1315723T1 (en) | The hydrochloride salt of 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione | |
| AU2002343036A1 (en) | 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical compositions comprising the same | |
| AU2002352479A1 (en) | 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus | |
| AU2002352481A1 (en) | 5- (4- (2- (n-methyl-n- (2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione nephtalenesulfonate salt and use against diabetes mellitus | |
| AU2002343052A1 (en) | Rosiglitazone edisylates and their use as antidiabetics | |
| WO2002028857A8 (en) | Polymorphs of pioglitazone hydrochloride and their use as antidiabetics | |
| AU2002352386A1 (en) | Hydrogensulfate salt of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thia zolidine-2,4-dione | |
| AU6255001A (en) | 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical | |
| HK1032905A (en) | 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical | |
| HK1032955A (en) | Hydrate of 5-[4-[2- (n-methyl-n- (2-pyridil)amino) ethoxy]benzyl] thiazolidine-2, 4-dione maleic acid salt | |
| AP1841A (en) | A thiazolidinedione derivative and its use as antidiabetic. | |
| AU2002350563A1 (en) | Pharmaceutical composition comprising a glitazone and a thiazolidinedione derivative, and use thereof for treating diabetes | |
| HK1028191A (en) | Composition comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazo lidine-2,4-dione | |
| HK1069107A (en) | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus | |
| HK1068883A (en) | 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical compositions comprising the same | |
| HK1056551A (en) | Thiazolidinedione salt for treatment of diabetes mellitus | |
| HK1055294A (en) | 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |